Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
IPO Year: 2015
Exchange: NASDAQ
Website: rocketpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2025 | $5.00 | Outperform → In-line | Evercore ISI |
| 5/28/2025 | Overweight → Neutral | Analyst | |
| 5/28/2025 | $2.00 | Neutral → Sell | Goldman |
| 5/28/2025 | $8.00 | Outperform → Market Perform | Leerink Partners |
| 5/28/2025 | $2.50 | Buy → Hold | Jefferies |
| 5/28/2025 | $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 5/27/2025 | Buy → Hold | TD Cowen | |
| 5/27/2025 | Buy → Hold | Needham | |
| 3/12/2025 | $50.00 | Outperform | BMO Capital Markets |
| 12/30/2024 | $32.00 | Outperform | Wedbush |
8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)
8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
144 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)
8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
10-Q - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)
SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)
DEFA14A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00
Analyst downgraded Rocket Pharmaceuticals from Overweight to Neutral
Goldman downgraded Rocket Pharmaceuticals from Neutral to Sell and set a new price target of $2.00
Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform and set a new price target of $8.00
Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and set a new price target of $2.50
Morgan Stanley downgraded Rocket Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $7.00
TD Cowen downgraded Rocket Pharmaceuticals from Buy to Hold
Needham downgraded Rocket Pharmaceuticals from Buy to Hold
BMO Capital Markets initiated coverage of Rocket Pharmaceuticals with a rating of Outperform and set a new price target of $50.00
Wedbush initiated coverage of Rocket Pharmaceuticals with a rating of Outperform and set a new price target of $32.00